EU approves Roche's Perjeta for metastatic breast cancer

03/5/2013 | Fox Business

The European Medicines Agency OK'd Roche Holding's Perjeta, or pertuzumab, in combination with trastuzumab and docetaxel, to treat women with previously untreated HER2-positive metastatic breast cancer. The approval followed the release of data from a late-stage trial, which showed that patients who took a combination of Perjeta, trastuzumab and chemotherapy survived 6.1 months longer without their disease progressing than those who received trastuzumab and chemotherapy.

View Full Article in:

Fox Business

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN